148 related articles for article (PubMed ID: 19622902)
1. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
[TBL] [Abstract][Full Text] [Related]
2. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
3. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
4. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
6. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
[TBL] [Abstract][Full Text] [Related]
7. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
Hollywood E
Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
[TBL] [Abstract][Full Text] [Related]
8. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
[TBL] [Abstract][Full Text] [Related]
9. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
Giuliani J; Marzola M
J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
[TBL] [Abstract][Full Text] [Related]
10. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Guo GF; Xia LP; Zhang B; Jiang WQ; Liu MZ; Hu PL; Chen XX; Qiu HJ; Zhou FF
Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
[TBL] [Abstract][Full Text] [Related]
12. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
13. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Jatoi A; Nguyen PL
Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
Cignola S; Gonella S; Alessandra B; Palese A
Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
Ma AT; Ma BB; Lei KI; Mo FK; Chan AT
Hong Kong Med J; 2010 Jun; 16(3):207-12. PubMed ID: 20519757
[TBL] [Abstract][Full Text] [Related]
16. Rash correlates with tumour response after cetuximab.
Susman E
Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536688
[No Abstract] [Full Text] [Related]
17. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
18. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Saltz LB; Meropol NJ; Loehrer PJ; Needle MN; Kopit J; Mayer RJ
J Clin Oncol; 2004 Apr; 22(7):1201-8. PubMed ID: 14993230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]